Merit Medical Systems Inc MMSI
We take great care to ensure that the data presented and summarized in this overview for MERIT MEDICAL SYSTEMS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MMSI
View all-
Black Rock Inc. New York, NY8.91MShares$780 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$582 Million0.01% of portfolio
-
State Street Corp Boston, MA2.22MShares$194 Million0.01% of portfolio
-
Conestoga Capital Advisors, LLC2.19MShares$191 Million2.92% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.82MShares$159 Million0.63% of portfolio
-
Invesco Ltd. Atlanta, GA1.58MShares$139 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C31.46MShares$128 Million0.17% of portfolio
-
Geode Capital Management, LLC Boston, MA1.44MShares$126 Million0.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx1.38MShares$121 Million2.21% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.35MShares$118 Million0.02% of portfolio
Latest Institutional Activity in MMSI
Top Purchases
Top Sells
About MMSI
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Insider Transactions at MMSI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2025
|
Martha Goldberg Aronson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
19,594
+50.0%
|
-
|
|
Aug 29
2025
|
Fred P Lampropoulos President and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
1,454
-14.94%
|
$130,860
$90.54 P/Share
|
|
Aug 29
2025
|
Fred P Lampropoulos President and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,000
+17.04%
|
$110,000
$55.73 P/Share
|
|
Aug 29
2025
|
Fred P Lampropoulos President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
124,824
-10.36%
|
$11,234,160
$90.54 P/Share
|
|
Aug 29
2025
|
Fred P Lampropoulos President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
159,151
+11.67%
|
$8,753,305
$55.73 P/Share
|
|
Aug 22
2025
|
Lynne Ward |
SELL
Open market or private sale
|
Direct |
3,000
-18.98%
|
$264,000
$88.56 P/Share
|
|
Aug 22
2025
|
Lynne Ward |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+15.95%
|
$102,000
$34.46 P/Share
|
|
Aug 11
2025
|
Lynne Ward |
SELL
Open market or private sale
|
Direct |
2,433
-15.96%
|
$204,372
$84.89 P/Share
|
|
Aug 11
2025
|
Lynne Ward |
BUY
Exercise of conversion of derivative security
|
Direct |
2,433
+13.77%
|
$82,722
$34.46 P/Share
|
|
Jun 13
2025
|
Raul Parra Jr. CFO AND TREASURER |
SELL
Open market or private sale
|
Direct |
15,181
-38.55%
|
$1,411,833
$93.75 P/Share
|
|
Jun 13
2025
|
Raul Parra Jr. CFO AND TREASURER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,181
+17.24%
|
$910,860
$60.64 P/Share
|
|
Jun 10
2025
|
Fred P Lampropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
400
-0.04%
|
$38,000
$95.61 P/Share
|
|
Jun 05
2025
|
Fred P Lampropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.95%
|
$950,000
$95.19 P/Share
|
|
Jun 02
2025
|
Michael R Mcdonnell |
SELL
Open market or private sale
|
Direct |
1,750
-21.49%
|
$164,500
$94.51 P/Share
|
|
Jun 02
2025
|
Michel James Voigt CHIEF HUMAN RESOURCES OFFICER |
SELL
Bona fide gift
|
Direct |
55
-0.25%
|
-
|
|
May 30
2025
|
David Floyd |
SELL
Open market or private sale
|
Indirect |
3,515
-41.87%
|
$330,410
$94.16 P/Share
|
|
May 30
2025
|
Michael R Mcdonnell |
SELL
Open market or private sale
|
Direct |
1,750
-17.69%
|
$164,500
$94.3 P/Share
|
|
May 30
2025
|
Fred P Lampropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.94%
|
$950,000
$95.12 P/Share
|
|
May 27
2025
|
Fred P Lampropoulos President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-1.84%
|
$1,920,000
$96.54 P/Share
|
|
May 15
2025
|
Thomas James Gunderson |
BUY
Grant, award, or other acquisition
|
Direct |
2,152
+5.64%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 174K shares |
|---|---|
| Exercise of conversion of derivative security | 367K shares |
| Payment of exercise price or tax liability | 202K shares |
|---|---|
| Open market or private sale | 238K shares |
| Bona fide gift | 5.42K shares |